Stockscreener 앱 받기
228.40
1.53%
-3.55
시간 외 거래:
229.52
1.12
+0.49%
전일 마감가:
$231.95
열려 있는:
$229.29
하루 거래량:
1.06M
Relative Volume:
0.81
시가총액:
$31.85B
수익:
$1.96B
순이익/손실:
$-253.24M
주가수익비율:
-120.13
EPS:
-1.9012
순현금흐름:
$94.06M
1주 성능:
-4.49%
1개월 성능:
+11.81%
6개월 성능:
+38.14%
1년 성능:
+37.14%
1일 변동 폭
$227.00
$232.76
1주일 범위
$225.58
$241.45
52주 변동 폭
$125.38
$246.90
Natera Inc Stock (NTRA) Company Profile
명칭
Natera Inc
전화
650-249-9090
주소
13011 MCCALLEN PASS, AUSTIN, CA
NTRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
228.40 | 32.35B | 1.96B | -253.24M | 94.06M | -1.9012 |
|
TMO
Thermo Fisher Scientific Inc
|
575.91 | 215.01B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
228.53 | 159.87B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
700.55 | 56.23B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
140.60 | 39.54B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
223.63 | 37.85B | 15.90B | 1.28B | 2.21B | 7.2842 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-10-27 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | 재개 | Wells Fargo | Equal Weight |
| 2025-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-08 | 재개 | Craig Hallum | Buy |
| 2024-02-20 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-11-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 개시 | Stephens | Overweight |
| 2022-03-08 | 개시 | Goldman | Buy |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-09-28 | 개시 | Morgan Stanley | Overweight |
| 2020-09-17 | 개시 | SVB Leerink | Outperform |
| 2020-06-10 | 재개 | Piper Sandler | Overweight |
| 2020-05-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 개시 | JP Morgan | Neutral |
| 2018-07-05 | 재확인 | Piper Jaffray | Overweight |
| 2017-08-07 | 재확인 | Morgan Stanley | Overweight |
| 2016-11-10 | 재확인 | The Benchmark Company | Buy |
| 2016-05-23 | 재확인 | The Benchmark Company | Buy |
| 2016-05-11 | 재확인 | The Benchmark Company | Buy |
| 2016-04-19 | 개시 | The Benchmark Company | Buy |
| 2015-09-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2015-08-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 개시 | Robert W. Baird | Outperform |
| 2015-07-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 개시 | Piper Jaffray | Overweight |
| 2015-07-27 | 개시 | Wedbush | Neutral |
모두보기
Natera Inc 주식(NTRA)의 최신 뉴스
Barclays Raises Natera (NTRA) Price Target to $270 | NTRA Stock News - GuruFocus
NTRA: JP Morgan Raises Price Target to $260 with Overweight Rati - GuruFocus
Natera (NASDAQ:NTRA) Given New $260.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Natera dismisses appeal in patent case against NeoGenomics - Investing.com India
Natera dismisses appeal in patent case against NeoGenomics By Investing.com - Investing.com Canada
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litig - pharmiweb.com
NeoGenomics Says Natera Withdraws Appeal in Patent Case - marketscreener.com
Neogenomics announces that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation - marketscreener.com
Neogenomics Announces That Natera Has Voluntarily Withdrawn Its Appeal In Ongoing RaDaR Patent Litigation - TradingView — Track All Markets
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation - Business Wire
Marex Group plc Makes New Investment in Natera, Inc. $NTRA - MarketBeat
Castleark Management LLC Has $5.87 Million Stake in Natera, Inc. $NTRA - MarketBeat
Natera (NTRA): Assessing Valuation After Strong Multi‑Year Share Price Rally - simplywall.st
Holocene Advisors LP Boosts Stake in Natera, Inc. $NTRA - MarketBeat
Fullerton Fund Management Co Ltd. Has $1.05 Million Holdings in Natera, Inc. $NTRA - MarketBeat
Natera, Inc. $NTRA Shares Bought by Nikko Asset Management Americas Inc. - MarketBeat
Natera, Inc. (NASDAQ:NTRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Engineers Gate Manager LP Sells 30,042 Shares of Natera, Inc. $NTRA - MarketBeat
GCM Grosvenor Holdings LLC Sells 6,475 Shares of Natera, Inc. $NTRA - MarketBeat
Gilder Gagnon Howe & Co. LLC Decreases Stake in Natera, Inc. $NTRA - MarketBeat
Bellevue Group AG Raises Stock Position in Natera, Inc. $NTRA - MarketBeat
AQR Capital Management LLC Boosts Holdings in Natera, Inc. $NTRA - MarketBeat
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Exelixis (EXEL) and Natera (NTRA) - The Globe and Mail
Caption Management LLC Takes Position in Natera, Inc. $NTRA - MarketBeat
Natera (NTRA) Joins Phase II Breast Cancer Study with Innovative DNA Testing - GuruFocus
Maverick Capital Ltd. Reduces Position in Natera, Inc. $NTRA - MarketBeat
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer - Yahoo Finance
Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know - MSN
Natera Completes Acquisition Of Foresight Diagnostics For Up To $450 Million - Pulse 2.0
Natera New Test Data Could Change How Doctors Manage Breast CancerNatera (NASDAQ:NTRA) - Benzinga
Is It Too Late to Consider Natera After a 511% Three Year Surge? - simplywall.st
Natera stock rating reiterated at Buy by TD Cowen on solid momentum - Investing.com India
Is It Too Late To Consider Natera After Its Recent 12.8% Price Surge? - Yahoo Finance
California Public Employees Retirement System Purchases 29,296 Shares of Natera, Inc. $NTRA - MarketBeat
Frontier Capital Management Co. LLC Has $65.04 Million Position in Natera, Inc. $NTRA - MarketBeat
Baird Financial Group Inc. Has $4.50 Million Stock Holdings in Natera, Inc. $NTRA - MarketBeat
Natera, Inc. $NTRA Shares Sold by Amundi - MarketBeat
Natera (NTRA) Unveils Promising Results from Phase III Breast Ca - GuruFocus
Natera (NASDAQ: NTRA) PALLAS: Signatera MRD‑positive group shows 13.4‑21.5 hazard ratios - Stock Titan
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer - Yahoo Finance
Natera acquires Foresight Diagnostics for up to $450M - MedTech Dive
Preimplantation Genetics Diagnosis Market size to exceed - openPR.com
Natera, Inc. $NTRA Stake Lowered by Blue Water Life Science Advisors LP - MarketBeat
Cerity Partners LLC Boosts Holdings in Natera, Inc. $NTRA - MarketBeat
Rowan Chapman Sells 4,366 Shares of Natera (NASDAQ:NTRA) Stock - MarketBeat
Natera director Chapman sells shares for $1.06 million By Investing.com - Investing.com South Africa
Natera director Chapman sells shares for $1.06 million - Investing.com
What's Driving the Market Sentiment Around Natera Inc? - Benzinga
Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna Makes New $1.24 Million Investment in Natera, Inc. $NTRA - MarketBeat
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting - marketscreener.com
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera - Wilson Sonsini
Natera Inc (NTRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.35%
0.32%
자본화:
|
볼륨(24시간):